Procalcitonin and qSOFA as a Marker of Mortality in Sepsis.

IF 1.4 Q4 PHARMACOLOGY & PHARMACY
A. Parrey, Manzoor Koka, B. Kasana, Mohd Ismail
{"title":"Procalcitonin and qSOFA as a Marker of Mortality in Sepsis.","authors":"A. Parrey, Manzoor Koka, B. Kasana, Mohd Ismail","doi":"10.2174/0115748871288534240322083746","DOIUrl":null,"url":null,"abstract":"BACKGROUND\nSepsis is a life-threatening organ dysfunction caused by a dysregulated host response to infection. The qSOFA and procalcitonin are currently used for both diagnostic as well as prognostic purposes.\n\n\nOBJECTIVE\nTo explore the combined use of day one procalcitonin level and qSOFA scores for prognostication of sepsis-related mortality Design: This was a prospective observational study.\n\n\nPARTICIPANTS\nAll patients who fulfilled the inclusion criteria for sepsis with an age of more than 16 years were enrolled in the study Results: In this study of 211 patients, 15 patients died (7.1%) during hospital stay. Among the 15 patients who died, the highest mortality of 29.4% qSOFA of \"2\" had a mortality of 12.8%),qSOFA of \"1\" had a mortality of 1% and qSOFA of \"0\" had zero mortality. In this study, procalcitonin had a statistically significant positive correlation/association with both qSOFA and mortality.\n\n\nCONCLUSION\nThe qSOFA and procalcitonin at presentation to the emergency department in septic patients have a significant correlation with mortality in patients hospitalized with sepsis. Obtaining these two parameters at presentation will help in managing aggressively these patients who at presentation have higher qSOFA and procalcitonin levels.","PeriodicalId":21174,"journal":{"name":"Reviews on recent clinical trials","volume":null,"pages":null},"PeriodicalIF":1.4000,"publicationDate":"2024-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Reviews on recent clinical trials","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/0115748871288534240322083746","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

BACKGROUND Sepsis is a life-threatening organ dysfunction caused by a dysregulated host response to infection. The qSOFA and procalcitonin are currently used for both diagnostic as well as prognostic purposes. OBJECTIVE To explore the combined use of day one procalcitonin level and qSOFA scores for prognostication of sepsis-related mortality Design: This was a prospective observational study. PARTICIPANTS All patients who fulfilled the inclusion criteria for sepsis with an age of more than 16 years were enrolled in the study Results: In this study of 211 patients, 15 patients died (7.1%) during hospital stay. Among the 15 patients who died, the highest mortality of 29.4% qSOFA of "2" had a mortality of 12.8%),qSOFA of "1" had a mortality of 1% and qSOFA of "0" had zero mortality. In this study, procalcitonin had a statistically significant positive correlation/association with both qSOFA and mortality. CONCLUSION The qSOFA and procalcitonin at presentation to the emergency department in septic patients have a significant correlation with mortality in patients hospitalized with sepsis. Obtaining these two parameters at presentation will help in managing aggressively these patients who at presentation have higher qSOFA and procalcitonin levels.
作为败血症死亡率标志物的降钙素原和 qSOFA。
背景败血症是一种危及生命的器官功能障碍,由宿主对感染的反应失调引起。目前,qSOFA 和降钙素原被用于诊断和预后目的。目的探讨如何将第一天的降钙素原水平和 qSOFA 评分联合用于脓毒症相关死亡率的预后:参与者:所有符合脓毒症纳入标准且年龄超过 16 岁的患者均纳入研究结果:在 211 名患者中,有 15 名患者的脓毒症相关死亡率为 0.5%:在这项有 211 名患者参与的研究中,有 15 名患者(7.1%)在住院期间死亡。在这 15 名死亡患者中,qSOFA 为 "2 "的患者死亡率最高(29.4%),qSOFA 为 "1 "的患者死亡率为 1%,qSOFA 为 "0 "的患者死亡率为零。在这项研究中,降钙素原与 qSOFA 和死亡率在统计学上有显著的正相关/关联。在患者就诊时获得这两个参数将有助于积极管理这些在就诊时qSOFA和降钙素原水平较高的患者。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Reviews on recent clinical trials
Reviews on recent clinical trials PHARMACOLOGY & PHARMACY-
CiteScore
3.10
自引率
5.30%
发文量
44
期刊介绍: Reviews on Recent Clinical Trials publishes frontier reviews on recent clinical trials of major importance. The journal"s aim is to publish the highest quality review articles in the field. Topics covered include: important Phase I – IV clinical trial studies, clinical investigations at all stages of development and therapeutics. The journal is essential reading for all researchers and clinicians involved in drug therapy and clinical trials.
文献相关原料
公司名称 产品信息 采购帮参考价格
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信